Related Experiment Video
Updated: Sep 30, 2025
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11.9K
Valid-NEO: A Multi-Omics Platform for Neoantigen Detection and Quantification from Limited Clinical Samples
Yuri Laguna Terai1, Chun Huang2, Baoli Wang3
1Complete Omics Inc., Baltimore, MD 21227, USA.
Cancers
|March 10, 2022
Summary
Valid-NEO directly identifies patient-specific neoantigens from minimal clinical samples, overcoming challenges in cancer immunotherapy development. This rapid, reproducible method aids in discovering neoantigen targets for diverse cancer treatments.
Area of Science:
- Oncology
- Immunology
- Analytical Chemistry
Background:
- Neoantigens presented on the cell membrane are crucial for cancer immunotherapies.
- Analyzing low-abundance neoantigens in clinical samples is a significant technical challenge.
- This difficulty hinders the broad application of neoantigen-based therapeutics for various cancers.
Purpose of the Study:
- To introduce Valid-NEO, an integrated system for identifying patient-specific neoantigen therapeutic targets.
- To enable direct observation and analysis of neoantigens without computational prediction.
- To provide a sensitive, rapid, and reproducible method for neoantigen discovery from limited clinical samples.
Main Methods:
- Direct observation and mass spectrometry analysis of neoantigens.
- Purification of neoantigens from tumor samples via recovery of HLA molecules using HLA antibodies.
- An integrated four-hour procedure for neoantigen identification and quantification.
Main Results:
- Valid-NEO successfully reveals patient-specific cancer neoantigen therapeutic targets.
- The system operates with high sensitivity, speed, and reproducibility.
- It effectively analyzes minute amounts of clinical samples.
Conclusions:
- Valid-NEO offers a novel approach to neoantigen identification and quantification.
- The system is particularly valuable for patients with limited sample availability.
- It has the potential to advance the development and application of neoantigen-based cancer immunotherapies worldwide.
